Patients with cardiovascular diseases can benefit from the combination of statins and PCSK9 inhibitors; the risk of developing cardiovascular diseases and strokes is reduced by 15%, and lipid levels are decreased by 60%.[30] Therefore, the combination of statins and PCSK9 inhibitors in the treatment of cardiovascular diseases can slow disease progression and contribute to a reduction in the incidence of cardiovascular events. The gene discussed is PCSK9; the disease is Stroke.